Research
A study is being conducted by the Clinical Immunization Safety Assessment (CISA) Network. This is a national network of experts in the field of immunization safety studies. The study is open to children with congenital anomalies consistent with 22q11.2 deletion syndrome such as DiGeorge syndrome (DGS) or velocardiofacial syndrome (VCFS). The purpose of this study is to help doctors determine which children with a deletion in the chromosome 22q11.2 can be safely immunized. There are no additional lab tests, shots, or medicines for this study. Your child will not be seen or examined. Study investigators at Columbia University Medical Center would review information that already exists in medial records. If you want more information about participating in this study please contact the Columbia University Research Assistants. Either Ximara Peckham (Phone: (212) 305-2876, Email: xp2101@columbia.edu) or Kathleen Jakob (Phone: (212) 305-2790, Email: kj160@columbia.edu). This study has been approved by the Columbia University Medical Center Institutional Review Board (IRB).